EUROFINS CEREP-REGR (ALECR.PA) Stock Fundamental Analysis

EPA:ALECR • FR0013256518

15900 EUR
0 (0%)
Last: Feb 18, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

Taking everything into account, ALECR scores 4 out of 10 in our fundamental rating. ALECR was compared to 18 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ALECR get a neutral evaluation. Nothing too spectacular is happening here. ALECR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • ALECR had positive earnings in the past year.
  • ALECR had positive earnings in each of the past 5 years.
  • ALECR had a negative operating cash flow in each of the past 5 years.
ALECR.PA Yearly Net Income VS EBIT VS OCF VS FCFALECR.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M 4M 6M 8M 10M

1.2 Ratios

  • ALECR's Return On Assets of 9.29% is amongst the best of the industry. ALECR outperforms 88.89% of its industry peers.
  • Looking at the Return On Equity, with a value of 10.82%, ALECR is in line with its industry, outperforming 55.56% of the companies in the same industry.
  • With a Return On Invested Capital value of 5.81%, ALECR is not doing good in the industry: 61.11% of the companies in the same industry are doing better.
  • The Average Return On Invested Capital over the past 3 years for ALECR is in line with the industry average of 9.81%.
Industry RankSector Rank
ROA 9.29%
ROE 10.82%
ROIC 5.81%
ROA(3y)11.69%
ROA(5y)12.73%
ROE(3y)14.25%
ROE(5y)16.06%
ROIC(3y)8.88%
ROIC(5y)10.64%
ALECR.PA Yearly ROA, ROE, ROICALECR.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

1.3 Margins

  • ALECR's Profit Margin of 16.86% is amongst the best of the industry. ALECR outperforms 88.89% of its industry peers.
  • In the last couple of years the Profit Margin of ALECR has grown nicely.
  • Looking at the Operating Margin, with a value of 12.72%, ALECR is doing worse than 61.11% of the companies in the same industry.
  • In the last couple of years the Operating Margin of ALECR has declined.
  • Looking at the Gross Margin, with a value of 85.67%, ALECR belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • ALECR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 12.72%
PM (TTM) 16.86%
GM 85.67%
OM growth 3Y-22.69%
OM growth 5Y-3.77%
PM growth 3Y-8.91%
PM growth 5Y4.87%
GM growth 3Y-0.31%
GM growth 5Y12.87%
ALECR.PA Yearly Profit, Operating, Gross MarginsALECR.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for ALECR remains at a similar level compared to 1 year ago.
  • Compared to 5 years ago, ALECR has more shares outstanding
  • Compared to 1 year ago, ALECR has a worse debt to assets ratio.
ALECR.PA Yearly Shares OutstandingALECR.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2K 4K 6K 8K
ALECR.PA Yearly Total Debt VS Total AssetsALECR.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • ALECR has an Altman-Z score of 11.35. This indicates that ALECR is financially healthy and has little risk of bankruptcy at the moment.
  • ALECR has a better Altman-Z score (11.35) than 100.00% of its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that ALECR is not too dependend on debt financing.
  • ALECR has a better Debt to Equity ratio (0.00) than 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.35
ROIC/WACCN/A
WACCN/A
ALECR.PA Yearly LT Debt VS Equity VS FCFALECR.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 7.27 indicates that ALECR has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 7.27, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • ALECR has a Quick Ratio of 6.83. This indicates that ALECR is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 6.83, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.27
Quick Ratio 6.83
ALECR.PA Yearly Current Assets VS Current LiabilitesALECR.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • ALECR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.41%.
  • Measured over the past years, ALECR shows a decrease in Earnings Per Share. The EPS has been decreasing by -3.78% on average per year.
  • Looking at the last year, ALECR shows a decrease in Revenue. The Revenue has decreased by -7.94% in the last year.
  • The Revenue has been growing slightly by 5.22% on average over the past years.
EPS 1Y (TTM)-6.41%
EPS 3Y-28.46%
EPS 5Y-3.78%
EPS Q2Q%-2.25%
Revenue 1Y (TTM)-7.94%
Revenue growth 3Y-1.31%
Revenue growth 5Y5.22%
Sales Q2Q%-8.7%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALECR.PA Yearly Revenue VS EstimatesALECR.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 22.24, ALECR is valued on the expensive side.
  • Based on the Price/Earnings ratio, ALECR is valued a bit cheaper than 61.11% of the companies in the same industry.
  • ALECR is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.27, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 22.24
Fwd PE N/A
ALECR.PA Price Earnings VS Forward Price EarningsALECR.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALECR.PA Per share dataALECR.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2K 4K 6K

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALECR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EUROFINS CEREP-REGR

EPA:ALECR (2/18/2026, 7:00:00 PM)

15900

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap159.00M
Revenue(TTM)41.00M
Net Income(TTM)7.25M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 22.24
Fwd PE N/A
P/S 3.7
P/FCF N/A
P/OCF N/A
P/B 2.37
P/tB 2.46
EV/EBITDA N/A
EPS(TTM)715
EY4.5%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4300
BVpS6700
TBVpS6476
PEG (NY)N/A
PEG (5Y)N/A
Graham Number10382
Profitability
Industry RankSector Rank
ROA 9.29%
ROE 10.82%
ROCE 7.94%
ROIC 5.81%
ROICexc 5.81%
ROICexgc 6%
OM 12.72%
PM (TTM) 16.86%
GM 85.67%
FCFM N/A
ROA(3y)11.69%
ROA(5y)12.73%
ROE(3y)14.25%
ROE(5y)16.06%
ROIC(3y)8.88%
ROIC(5y)10.64%
ROICexc(3y)10.25%
ROICexc(5y)11.89%
ROICexgc(3y)10.71%
ROICexgc(5y)12.51%
ROCE(3y)12.09%
ROCE(5y)14.49%
ROICexgc growth 3Y-34.97%
ROICexgc growth 5Y-16.9%
ROICexc growth 3Y-34.63%
ROICexc growth 5Y-16.09%
OM growth 3Y-22.69%
OM growth 5Y-3.77%
PM growth 3Y-8.91%
PM growth 5Y4.87%
GM growth 3Y-0.31%
GM growth 5Y12.87%
F-ScoreN/A
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.27
Quick Ratio 6.83
Altman-Z 11.35
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.41%
EPS 3Y-28.46%
EPS 5Y-3.78%
EPS Q2Q%-2.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.94%
Revenue growth 3Y-1.31%
Revenue growth 5Y5.22%
Sales Q2Q%-8.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.62%
EBIT growth 3Y-23.7%
EBIT growth 5Y1.26%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

EUROFINS CEREP-REGR / ALECR.PA FAQ

What is the ChartMill fundamental rating of EUROFINS CEREP-REGR (ALECR.PA) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALECR.PA.


Can you provide the valuation status for EUROFINS CEREP-REGR?

ChartMill assigns a valuation rating of 1 / 10 to EUROFINS CEREP-REGR (ALECR.PA). This can be considered as Overvalued.


How profitable is EUROFINS CEREP-REGR (ALECR.PA) stock?

EUROFINS CEREP-REGR (ALECR.PA) has a profitability rating of 5 / 10.


What are the PE and PB ratios of EUROFINS CEREP-REGR (ALECR.PA) stock?

The Price/Earnings (PE) ratio for EUROFINS CEREP-REGR (ALECR.PA) is 22.24 and the Price/Book (PB) ratio is 2.37.